glycyl-prolyl-arginyl-valyl-valyl-glutamic acid has been researched along with hirudin in 1 studies
| Studies (glycyl-prolyl-arginyl-valyl-valyl-glutamic acid) | Trials (glycyl-prolyl-arginyl-valyl-valyl-glutamic acid) | Recent Studies (post-2010) (glycyl-prolyl-arginyl-valyl-valyl-glutamic acid) | Studies (hirudin) | Trials (hirudin) | Recent Studies (post-2010) (hirudin) |
|---|---|---|---|---|---|
| 6 | 1 | 0 | 3,658 | 378 | 995 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argiriou, S; Dempfle, CE; Heene, DL; Kucher, K; Müller-Peltzer, H; Rübsamen, K | 1 |
1 other study(ies) available for glycyl-prolyl-arginyl-valyl-valyl-glutamic acid and hirudin
| Article | Year |
|---|---|
Analysis of fibrin formation and proteolysis during intravenous administration of ancrod.
Topics: Adult; alpha-2-Antiplasmin; Ancrod; Biopolymers; Calcium Chloride; Chromatography, Gel; Enzyme Activation; Factor XIII; Female; Fibrin; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysin; Fibrinolysis; Fibrinolytic Agents; Fibrinopeptide A; Hirudins; Humans; Infusions, Intravenous; Macromolecular Substances; Male; Middle Aged; Peptide Fragments; Plasminogen; Recombinant Proteins; Solubility; Thrombin; Tissue Plasminogen Activator | 2000 |